ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Jones Trading maintains Buy on ORIC, $17 target on positive data
Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...